Generic Name and Formulations:
Ticagrelor 60mg, 90mg; tabs.
Indications for BRILINTA:
To reduce the rate of cardiovascular death, MI, and stroke in patients with acute coronary syndrome (ACS) or history of MI. To reduce the rate of stent thrombosis in patients who have been stented for ACS.
Swallow whole; if unable to swallow, may crush tabs, then mix with water and drink or give via NG tube (CH8 or greater). Initially 180mg loading dose, continue with 90mg twice daily during the first year; after one year, give 60mg twice daily. After the initial loading dose of aspirin, take ticagrelor with maintenance dose of aspirin 75–100mg daily.
History of intracranial hemorrhage. Active pathological bleeding (eg, peptic ulcer, intracranial hemorrhage).
Increased risk of bleeding. Do not start in patients planned to undergo urgent CABG. Premature discontinuation increases risk for CV events (eg, MI, stroke, death). Avoid interruption of treatment; if temporarily discontinued, restart as soon as possible. When possible, interrupt therapy for 5 days prior to surgery (those with major bleeding risk); resume upon hemostasis. Effectiveness reduced with aspirin maintenance dose >100mg; avoid. History of sick sinus syndrome, 2nd or 3rd-degree AV block or bradycardia-related syncope without a pacemaker: increased risk of bradyarrhythmias. Moderate hepatic impairment. Severe hepatic impairment: avoid. Pregnancy (Cat.C). Nursing mothers: not recommended.
Concomitant other oral P2Y12 platelet inhibitor: not recommended. Avoid concomitant strong CYP3A inhibitors (eg, ketoconazole, itraconazole, voriconazole, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir, telithromycin) or potent CYP3A inducers (eg, rifampin, phenytoin, carbamazepine, phenobarbital). Potentiates simvastatin, lovastatin; avoid >40mg/day doses. Monitor digoxin during ticagrelor initiation and dose adjustments.
P2Y12 platelet inhibitor (cyclopentyltriazolopyrimidine).
Bleeding (may be fatal), dyspnea (consider other alternatives if intolerable), dizziness, nausea, diarrhea; ventricular pauses.
Tabs 60mg—60; 90mg—14, 60
Neurology Advisor Articles
- Clarifying Cardiovascular Risk in Migraine
- Parkinson Disease Symptom Fluctuations Well-Managed With Adaptive Deep Brain Stimulation
- More Evidence Supports Benefits of Cannabidiol for Treatment-Resistant Epilepsy
- Monthly Erenumab Reduces Frequency of Episodic Migraine
- Reduced Risk for Multiple Sclerosis Linked to Greater Sun Exposure
- Tamsulosin Associated With Dementia Risk in Older Patients With BPH
- FDA Approves Blood Test to Assess Concussion
- Gait Difficulty in Parkinson Disease May Be Associated With More Progressive Disease Course
- Tau PET a Useful Biomarker for Alzheimer Disease Risk and Progression
- Multiple Sclerosis Drug Zinbryta Withdrawn From the Market
- Incidence of Delayed Traumatic Intracranial Hemorrhage Low in Older Adults With Blunt Head Trauma
- Older Epilepsy Patients More Likely to Experience AED, Non-AED Drug Interaction
- Female Gender, Natalizumab Exposure Associated With Increased Lymphopenia Risk in FNG-Treated MS
- Accelerated Cognitive Decline Associated With Retinopathy
- Treatment Effects Often Exaggerated in Early Clinical Studies